Article http://dx.doi.org/10.26855/ijcemr.2024.04.020

To Analyze the Immunomodulatory Effects of Anti-Il-6 Receptor Drug Tocilizumab in Giant Cell Arteritis (GCA)


Yanyan Zhang*, Tianqian Jia, Xiaojuan Li, Yueyan Wang

School of Medical Engineering, Haojing College of Shaanxi University of Science & Technology, Xi'an, Shaanxi, China.

*Corresponding author: Yanyan Zhang

Published: May 24,2024


Giant Cell Arteritis (GCA) is an inflammatory symptom that affects blood vessels in middle-aged and elderly people. The disease involves large and medium-sized arteries in patients, especially the temporal arteries. The appearance of diseases affects the physical health of patients to a certain extent. Interleukin-6 plays an important role in a variety of immune responses and inflammatory responses. Tocilizumab is a kind of humanized monoclonal anti-body that can bind and block the IL-6 receptor in a specific way, inhibit the IL-6 mediated signal transduction, alleviate inflammatory responses, and re-duce inflammatory damage. This article is divided into four parts and describes the research progress of the immunomadological effects of anti-IL-6 receptor drug tocilizumab in giant cell arteritis. Firstly, the basic characteristics and mechanism of tocilizumab were analyzed, including chemical structure and biological activity, pharmacokinetic characteristics, and safety of tocilizumab. Secondly, the application of tocilizumab in the treatment of giant cell arteritis was discussed, including the efficacy analysis, dosage, and course of treatment. The challenges and limitations of tocilizumab in the treatment of giant cell arteritis were discussed again. Finally, the prospect of the proposition is summarized, hoping that this paper can provide reference materials for related personnel's research work.


[1] Tan Yue, GE Ningning, Peng Jing, et al. Signal mining and evaluation of adverse drug events in children with tocilizumab and infliximab [J]. Chin J Clinical Pharmacology, 2024, 40 (05): 732-736.

[2] Albahdal S A, Alotaibi M A, Alanazi A M,  et al. Cost-consequence analysis of tocilizumab versus adalimumab and etanercept among rheumatoid arthritis patients in  Saudi Arabia: a single-center study [J]. Cost-effectiveness and Resource Allocation: C/E, 2024, 22 (1): 14.

[3] Zhang Xue, Li Dake. Rheumatic immune-related adverse reactions and treatment of immune checkpoint inhibitors [J]. Cancer Prevention and Treatment Research, 2020, 47 (11): 894-899.

[4] Zhang Weiqin, Zhao Huawei, Wang Zhenzhen, et al. Treatment of a child with refractory anti-NMDAR encephalitis with tocili-zumab: case report and literature review [J/OL]. Chinese Modern Applied Pharmacy, 1-5 [2024-03-27].

[5] Liu Xiyu, Sun Mengyao, Ren Na, et al. The role of T cell-associated signaling pathways in the pathogenesis of Takayasu's arteritis [J]. Chin J Lab Diagnostics, 2023, 27 (04): 501-505.

[6] Han R. Diagnosis and treatment of a case of giant cell arteritis with paroxysmal visual impairment [J]. Chinese Journal of Practical Rural Doctor, 2022, 29 (01): 71-74.

[7] Zhu L S. The mechanism of Porphyromonas gingivalis affecting the immune response of macrophages and the screening of anti-bacterial Chinese medicine monomers [D]. Shanghai University of Traditional Chinese Medicine, 2021.

[8] Xi X Q. Giant cell arteritis and polymyalgia rheumatica [J]. Chinese Journal of Practical Rural Doctor, 2020, 27 (02): 9-11. (in Chinese)

[9] Tang Yanni, Yuan Yiming, Zhang Yingting. Giant cell arteritis with fever as the initial symptom: a case report [J]. Chin J Clinol (Electronic Edition), 2019, 13 (10): 798-800.

[10] Wang Yu, Zhang Yun, Wang Dongmei, et al. Clinical characteristics of giant cell arteritis with positive pathology and its correlation with pathological results [J]. Basic Medicine & Clinic, 2019, 39 (05): 731-734.

[11] Wu Xiao, Zheng Yuehong. Progress in diagnosis and treatment of giant cell arteritis causing intermittent claudication of the lower limbs [J]. Chin J Multiple Organ Diseases, 2018, 17 (08): 617-620.

[12] Chen Sufen, Zhang Meichen, Dong Zhao, et al. Clinical and prognostic analysis of giant cell arteritis patients presenting with pain. Chinese Journal of Pain Medicine, 2018, 24 (08): 610-614.

[13] Yin Yue, Zhang Yun, Zeng Xuejun. Giant cell arteritis and fever of unknown origin in the elderly [J]. Basic Medicine & Clinic, 2018, 38 (08): 1168-1172.

[14] GAO Kaiyan, Yuan Fenghong, Xu Wei, et al. PET-CT diagnosis of giant cell arteritis: report of 4 cases and review of literature [J]. Chongqing Med, 2017, 46 (33): 4673-4675+4679.

[15] Chen Xiaoming. The first drug Actemra(tocilizumab) approved by FDA for the treatment of giant cell arteritis [J]. Journal of Guangdong Pharmaceutical University, 2017, 33 (03): 289.

[16] Tong Chunmei. A case of posterior scleral inflammatory giant cell arteritis [J]. Chinese Journal of PLA Medicine, 2017, 29 (02): 2+117.

[17] Huang Huifang, Huo Lijuan, Guo Junzhi, et al. Giant cell arteritis diagnosed by positron emission computed tomography/CT: a case report with abdominal pain and fatigue [J]. Chin Materia Medica & Clinic, 2017, 17 (01): 151-152.

[18] Yuan Xiang, Li Xiaomei. Application of imaging techniques in the diagnosis of giant cell arteritis [J]. Chin J Clinical Immunology and Allergy, 2016, 10 (02): 170-174.

[19] Wang Limin, Yu Jing, Gao Mingli. Giant cell arteritis with fever as the first manifestation: a case report and literature analysis [J]. Shanxi Med J, 2016, 45 (09): 1083-1087.

[20] Wang Youying. Curative effect of giant cell arteritis and polymyalgia rheumatica [J]. Digest of World Latest Medical Information, 2015, 15 (A2): 90-91.

[21] T. Klink, J. Geiger, M. Both, et al. Giant cell arteritis: accuracy of MRI in the initial diagnosis of superficial cranial arteries: results from a multi-center trial [J]. International Journal of Medical Radiology, 2015, 38 (01): 78.

How to cite this paper

To Analyze the Immunomodulatory Effects of Anti-Il-6 Receptor Drug Tocilizumab in Giant Cell Arteritis (GCA)

How to cite this paper: Yanyan Zhang, Tianqian Jia, Xiaojuan Li, Yueyan Wang. (2024) To Analyze the Immunomodulatory Effects of Anti-Il-6 Receptor Drug Tocilizumab in Giant Cell Arteritis (GCA). International Journal of Clinical and Experimental Medicine Research8(2), 296-299.

DOI: http://dx.doi.org/10.26855/ijcemr.2024.04.020